This study evaluates the effects of ALA on the pathophysiological features of FRDA in patient-derived cellular models, aiming to determine its therapeutic potential in alleviating oxidative stress and restoring frataxin expression and mitochondrial function. Here, FXN is linked to Friedreich ataxia.